RecruitingNot Applicable

Observational Study of Pediatric Rheumatic Diseases: The CARRA Registry

United States20,000 participantsStarted 2015-07

Plain-language summary

Continuation of the CARRA Registry as described in the protocol will support data collection on patients with pediatric-onset rheumatic diseases. The CARRA Registry will form the basis for future CARRA studies. In particular, this observational registry will be used to answer pressing questions about therapeutics used to treat pediatric rheumatic diseases, including safety questions.

Who can participate

Age range21 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Onset of rheumatic disease prior to age 16 years for JIA and onset prior to age 19 years for all other rheumatic diseases (see appendix A).
✓. Subject (and/or parent/legal guardian when required) is able to provide written informed consent and willing to comply with study procedures.
✓. Subject and/or parent/legal guardian is willing to be contacted in the future by study staff.

What they're measuring

Prospectively collect essential data elements from children, adolescents and young adults with pediatric rheumatic diseases

Timeframe: Approximately 10 years

Evaluate the safety of therapeutic agents in persons with pediatric onset rheumatic diseases

Timeframe: Approximately 10 years

Trial details

NCT IDNCT02418442

SponsorDuke University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2028-06

Contact for this trial

Mara L Becker, MD, MSCE

(919) 419-5032 mara.becker@duke.edu

View on ClinicalTrials.gov More Rheumatic Joint Disease trials